low healthVERIFIED
Gilead-Backed Aspen Neuroscience Shares Decline 2% After US IPO
📍 United States, US·🕐 50m ago·2 outlets
Aspen Neuroscience Inc., a clinical-stage developer of cell therapies, fell 2% after raising about $140.6 million in a US initial public offering.
How sure are we
✓ Verified · 2 outlets
Two or more outlets reported this story and its reliability score reached 65%, so WorldPulse marks it verified. That means more than one outlet says so, not that it is proven true.
Who reported it
Location
Verification Log1
cross checkconfirmed90%
[Claude] Both other reports cover the same Aspen Neuroscience IPO pricing at $15 per share, which is consistent with Report 1's account of the IPO and its roughly $140.6 million raise.
50m agoPowered by WorldPulse Verification Engine
Reliability
Reliability ScoreVery high
95%Independent outlets2
Statusverified
AI checknone yet
Community flags0
Score bands
Very high80–100%
A highly rated outlet, or several independent outletsHigh60–79%
One well-rated outlet so farModerate40–59%
A lower-rated or state-run outlet, or one report of something seriousLow20–39%
A low-rated outlet on a serious or sensitive storyVery low0–19%
Treat it as unconfirmedWhat moves the score
◎
Outlet ratingThe outlet’s rating in WorldPulse’s list of sources starts the score
⇄
Independent outletsEach further outlet that reports the story closes 40% of the gap to 98%
±
Report detailsA few points either way: a summary and a place add a little; state-run outlets on conflict, politics or security, and single reports marked high or critical, lose some
Not in the score: AI checks and reader flags. Verified is separate: two or more independent outlets and a score of at least 65%.
Very high · How we score this
Risk Score
low risk